1,133 reports of this reaction
3.1% of all RIFAXIMIN reports
#4 most reported adverse reaction
OFF LABEL USE is the #4 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 1,133 FDA adverse event reports linking RIFAXIMIN to OFF LABEL USE. This represents approximately 3.1% of all 37,072 adverse event reports for this drug.
Patients taking RIFAXIMIN who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among RIFAXIMIN users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for RIFAXIMIN:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,133 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.1% of all adverse event reports for RIFAXIMIN, making it a notable side effect.
If you experience off label use while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.